Intercell and Vivalis Provide Update on the Progress Towards Intended Merger
News Jan 30, 2013
On 16 December 2012, Vivalis SA and Intercell AG have announced their intention to merge and form Valneva SE (“Valneva”).
The merger is progressing well, in line with the timeline communicated at time of announcement:
• The French merger document (Document E) has been registered by the Autorité des marchés financiers (AMF) on 23 January 2013
• The full set of applicable merger documents have been made available on Intercell and Vivalis websites
• Intercell and Vivalis General Meetings have been convened and will take place on 27 February 2013 and 4 March 2013 respectively
• Merger is expected to close in May 2013, after which Valneva intends to launch a EUR 40 million capital increase, subject to regulatory approval
Additionally, Vivalis and Intercell have finalized the proposed governance of Valneva, agreeing on the following initial Supervisory Board (Conseil de Surveillance) composition:
• Frédéric Grimaud (Chairman), Alain Munoz and Michel Gréco proposed by Vivalis
• Prof. Alexander von Gabain, James Sulat, and Prof. Hans Wigzell proposed by Intercell
• Anne-Marie Graffin proposed by the Fonds Stratégique d'Investissement (“FSI”), to be nominated upon closing of the planned capital increase
In addition to the listing of Valneva Ordinary Shares on NYSE Euronext Paris and on the Vienna Stock Exchange, Vivalis and Intercell have decided to also apply for the listing of the Preferred Shares on Euronext Paris, upon completion of the merger.
Thomas Lingelbach, future President and Chief Executive Officer of Valneva, and Franck Grimaud, future President and Chief Business Officer commented: "We are extremely pleased with the progress made on the merger and are moving according to our planned timeline. We expect the merger to close in May and are ready and very enthusiastic about the next phase."
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Studying Ebola-Host Cell Interaction Helps Find Targets for Antiviral DrugsNews
In some ways, the Ebola virus operates like a vampire; only after it is politely invited in to a host cell does it take up the task of destroying everything in its path. In a new study researchers seek to elucidate quantitatively the biomechanical mechanism of Ebola-host cell interaction, providing potential new targets for antiviral drug development.READ MORE
Insulin Goes Viral: Diabetes and Cancer-causing Mechanisms ExploredNews
Every cell in your body responds to the hormone insulin, and if that process starts to fail, you get diabetes. In an unexpected finding, scientists have identified four viruses that can produce insulin-like hormones that are active on human cells. The discovery brings new possibilities for revealing biological mechanisms that may cause diabetes or cancer.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018